Dr. Scott Dax has over 25 years of experience guiding research & development at both large pharmaceutical and small biotechnology companies. His leadership roles span chemistry, drug discovery, pharmacology and technology.

Prior to joining BioMotiv, Dr. Dax served as Chief Technology Officer at Galleon Pharmaceuticals, where he discovered and designed breathing control modulators to treat respiratory depression caused by opioid therapy without compromising analgesia. Scott’s research contributed to venture capital investments totaling greater than $60 million.

Dr. Dax also served as Analgesics Research Team Leader at Johnson & Johnson. Prior to Johnson & Johnson, he held positions at DuPont-Merck and Hoffmann-LaRoche working in the area of infectious diseases.

Dr. Dax is an inventor of nearly 100 issued patents worldwide and approximately 100 publications & presentations in peer-reviewed journal and professional societies. He earned his Masters and Doctorate degrees in chemistry at the University of Michigan and was an NIH post-doctoral awardee at the University of Wisconsin.